Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

ABSTRACT:

Background

Risk prediction models that incorporate biomarkers and clinicopathologic variables may be used to improve decision making after radical prostatectomy (RP). We compared two previously validated post-RP classifiers-the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) and the Decipher genomic classifier (GC)-to predict prostate cancer-specific mortality (CSM) in a contemporary cohort of RP patients.

Objective

To evaluate the combined prognostic ability of CAPRA-S and GC to predict CSM.

Design, setting, and participants

A cohort of 1010 patients at high risk of recurrence after RP were treated at the Mayo Clinic between 2000 and 2006. High risk was defined by any of the following: preoperative prostate-specific antigen >20 ng/ml, pathologic Gleason

SUBMITTER: Cooperberg MR 

PROVIDER: S-EPMC4282620 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature